A. Multiple clinical studies since 2003 have demonstrated the effectiveness of CXL in halting the progression of vision loss from keratoconus. The technology has been in wide spread use around the world, including throughout Europe where it received the CE Mark of approval in 2006. A decade later, the rigorous stamp of FDA approval was given on April 18, 2016. Studies show that CXL is effective for the majority of patients in stopping vision loss from keratoconus. Additionally, some patients will experience an improvement in vision due to a decrease in corneal steepening and myopia.